Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.
暂无分享,去创建一个
[1] M. V. St-Pierre,et al. Temporal variation in the disposition of theophylline and its metabolites , 1985, Clinical pharmacology and therapeutics.
[2] A. Freiburghaus,et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. , 1995, British journal of clinical pharmacology.
[3] L. Sansom,et al. A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission , 2004, European Journal of Clinical Pharmacology.
[4] E. Widdowson,et al. Chemical changes in skeletal muscle during development. , 1960, The Biochemical journal.
[5] B. Persson,et al. CEREBRAL BLOOD FLOW AND EXCHANGE OF OXYGEN, GLUCOSE, KETONE BODIES, LACTATE, PYRUVATE AND AMINO ACIDS IN INFANTS , 1976, Acta paediatrica Scandinavica.
[6] G. Schwartz,et al. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. , 1978, The Journal of pediatrics.
[7] Meindert Danhof,et al. Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.
[8] Nafziger An,et al. Sex-related differences in theophylline pharmacokinetics. , 1989 .
[9] J. Takeda,et al. LIVER BLOOD FLOW DURING HIGH FREQUENCY OSCILLATION AND CONVENTIONAL MECHANICAL VENTILATION , 1984 .
[10] R. Ogilvie,et al. Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. , 1976, The Journal of pediatrics.
[11] E. Widdowson,et al. The effect of growth and function on the chemical composition of soft tissues. , 1960, The Biochemical journal.
[12] Dale Hattis,et al. Physiologically Based Pharmacokinetic (PBPK) Modeling of Caffeine and Theophylline in Neonates and Adults: Implications for Assessing Children's Risks from Environmental Agents , 2004, Journal of toxicology and environmental health. Part A.
[13] É. Jacqz-Aigrain,et al. Pharmacokinetics of midazolam in critically ill neonates , 2004, European Journal of Clinical Pharmacology.
[14] Susan M Abdel-Rahman,et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.
[15] H. Boxenbaum. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin , 1980, Journal of Pharmacokinetics and Biopharmaceutics.
[16] C. Whight,et al. Echo Doppler assessment of cardiac output and its relation to growth in normal infants. , 1987, The American journal of cardiology.
[17] Shinichi Kobayashi,et al. Developmental Changes in Urinary Elimination of Theophylline and Its Metabolites in Pediatric Patients , 1999, Pediatric Research.
[18] M. J. Eadie,et al. The pharmacokinetics of midazolam in man , 2004, European Journal of Clinical Pharmacology.
[19] T. Cresteil,et al. Delayed ontogenesis of CYP1A2 in the human liver. , 1998, European journal of biochemistry.
[20] L. Paalzow,et al. Pharmacokinetics of theophylline in Ethiopian children of differing nutritional status , 2004, European Journal of Clinical Pharmacology.
[21] F. Tinahones,et al. Adipose tissue fatty acids and size and number of fat cells from birth to 9 years of age--a cross-sectional study in 96 boys. , 1996, Metabolism: clinical and experimental.
[22] M. Relling,et al. Hepatic drug clearance in children: studies with indocyanine green as a model substrate. , 1989, Journal of pharmaceutical sciences.
[23] S. Riegelman,et al. Nonlinear theophylline elimination , 1982, Clinical pharmacology and therapeutics.
[24] N. Baber,et al. Dose estimation for children. , 2003, British journal of clinical pharmacology.
[25] Harvey J Clewell,et al. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. , 2003, Regulatory toxicology and pharmacology : RTP.
[26] S. Haddad,et al. Physiological Modeling of Age-Specific Changes in the Pharmacokinetics of Organic Chemicals in Children , 2003, Journal of toxicology and environmental health. Part A.
[27] W. Jusko,et al. Effects of obesity and ancillary variables (dialysis time, drug, albumin, and fatty acid concentrations) on theophylline serum protein binding. , 1989, Biopharmaceutics & drug disposition.
[28] J. Dundee,et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. , 1988, British journal of anaesthesia.
[29] B. K. Park,et al. Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. , 1988, The Journal of pharmacology and experimental therapeutics.
[30] M Pelekis,et al. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. , 2001, Regulatory toxicology and pharmacology : RTP.
[31] G Benoni,et al. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. , 2001, Journal of pharmaceutical sciences.
[32] T. Cresteil,et al. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.
[33] B. Friis‐Hansen. WATER DISTRIBUTION IN THE FOETUS AND NEWBORN INFANT , 1983, Acta paediatrica Scandinavica. Supplement.
[34] G. L. Baker. Human adipose tissue composition and age. , 1969, The American journal of clinical nutrition.
[35] J. Fluhr,et al. Direct Comparison of Skin Physiology in Children and Adults with Bioengineering Methods , 2000, Pediatric dermatology.
[36] Sovitj Pou,et al. The Single‐Dose Pharmacokinetics of Midazolam and Its Primary Metabolite in Pediatric Patients after Oral and Intravenous Administration , 2001, Journal of clinical pharmacology.
[37] K. Mcculloch,et al. Alterations in theophylline metabolism during the first year of life , 1993, Clinical pharmacology and therapeutics.
[38] Paul Y. K. Wu,et al. Peripheral Blood Flow in the Neonate. 1. Changes in Total, Skin, and Muscle Blood Flow with Gestational and Postnatal Age , 1980, Pediatric Research.
[39] T. Cresteil,et al. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. , 1996, European journal of biochemistry.
[40] F. Simons,et al. Pharmacokinetics of Theophylline in Infancy , 1978, Journal of clinical pharmacology.
[41] N. Butte,et al. Body Composition during the First 2 Years of Life: An Updated Reference , 2000, Pediatric Research.
[42] R. Ogilvie,et al. Pharmacokinetics of intravenous theophylline , 1973, Clinical pharmacology and therapeutics.
[43] Jane Alcorn,et al. Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants Part I , 2002, Clinical pharmacokinetics.
[44] O. Linderkamp,et al. Estimation and prediction of blood volume in infants and children , 1977, European Journal of Pediatrics.
[45] D. Greenblatt,et al. Effect of Age, Gender, and Obesity on Midazolam Kinetics , 1984, Anesthesiology.
[46] D. Back,et al. Theophylline metabolism in human liver microsomes: inhibition studies. , 1996, The Journal of pharmacology and experimental therapeutics.
[47] R. Leggett,et al. Reference values for resting blood flow to organs of man. , 1989, Clinical physics and physiological measurement : an official journal of the Hospital Physicists' Association, Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations for Medical Physics.
[48] F. Haschke,et al. Body composition of reference children from birth to age 10 years. , 1982, The American journal of clinical nutrition.
[49] Ivan Nestorov,et al. Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.
[50] Lewis B. Sheiner,et al. Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[51] M. Weinberger,et al. Relationship of theophylline clearance to oral dosage in children with chronic asthma. , 1977, The Journal of pediatrics.
[52] T. Turmen,et al. Pharmacokinetics of diuretics and methylxanthines in the neonate , 1980, European Journal of Clinical Pharmacology.
[53] J. Magny,et al. Population pharmacokinetics of midazolam in neonates , 1994, Clinical pharmacology and therapeutics.
[54] D. Agbaba,et al. Dependence of the Renal Excretion of Theophylline on its Plasma Concentrations and Urine Flow Rate in Asthmatic Children , 1990, The Journal of pharmacy and pharmacology.
[55] Kannan Krishnan,et al. CHARACTERIZATION OF AGE-RELATED CHANGES IN BODY WEIGHT AND ORGAN WEIGHTS FROM BIRTH TO ADOLESCENCE IN HUMANS , 2001, Journal of toxicology and environmental health. Part A.
[56] W. Jusko,et al. Theophylline tissue partitioning and volume of distribution in normal and dietary-induced obese rats. , 1987, Biopharmaceutics & drug disposition.
[57] M. Rubin,et al. Maturation of renal function in childhood; clearance studies. , 1949, The Journal of clinical investigation.